BR112015029240A2 - composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo - Google Patents

composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo

Info

Publication number
BR112015029240A2
BR112015029240A2 BR112015029240A BR112015029240A BR112015029240A2 BR 112015029240 A2 BR112015029240 A2 BR 112015029240A2 BR 112015029240 A BR112015029240 A BR 112015029240A BR 112015029240 A BR112015029240 A BR 112015029240A BR 112015029240 A2 BR112015029240 A2 BR 112015029240A2
Authority
BR
Brazil
Prior art keywords
individual
compound
composition
nrlp3
inflammasome
Prior art date
Application number
BR112015029240A
Other languages
English (en)
Inventor
Abbate Antonio
Van Tassell Benjamin
Zhang Shijun
Original Assignee
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Commonwealth filed Critical Univ Virginia Commonwealth
Publication of BR112015029240A2 publication Critical patent/BR112015029240A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

resumo “composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo” a presente invenção se refere a inibidores que são agentes antiinflamatórios proporcionados, no mesmo modo que são proporcionados métodos de usar os análogos para inibir inflamação e evitar ou tratar doenças e condições associadas com inflamação, tal como insuficiência cardíaca e doenças autoimunes. ?? ?? ?? ?? 1/1
BR112015029240A 2013-05-21 2014-05-21 composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo BR112015029240A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361825623P 2013-05-21 2013-05-21
US201361901187P 2013-11-07 2013-11-07
PCT/US2014/038913 WO2014190015A1 (en) 2013-05-21 2014-05-21 Cryopyrin inhibitors for preventing and treating inflammation

Publications (1)

Publication Number Publication Date
BR112015029240A2 true BR112015029240A2 (pt) 2017-07-25

Family

ID=51934075

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015029240A BR112015029240A2 (pt) 2013-05-21 2014-05-21 composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo

Country Status (10)

Country Link
US (1) US10343985B2 (pt)
EP (1) EP2999691A4 (pt)
JP (1) JP2016522831A (pt)
KR (1) KR20160009667A (pt)
CN (1) CN105579433A (pt)
AU (1) AU2015258273A1 (pt)
BR (1) BR112015029240A2 (pt)
CA (1) CA2913154A1 (pt)
MX (1) MX2015016100A (pt)
WO (1) WO2014190015A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105237445A (zh) * 2015-10-20 2016-01-13 大连九信生物化工科技有限公司 一种4-[2-(5-氯-2-甲氧基苯甲酰胺)乙基]苯磺酰胺的合成工艺
EP3872070A1 (en) * 2016-04-18 2021-09-01 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
WO2018103583A1 (en) * 2016-12-05 2018-06-14 Zibo Anxuan Pharmaceutical Science And Technology Co., Ltd. N-hydroxy-benzene-sulfonamide derivatives and their uses thereof
CN116036069A (zh) * 2017-01-06 2023-05-02 欧拉泰克治疗有限责任公司 用于治疗心血管疾病的方法
CR20190356A (es) * 2017-01-23 2019-11-20 Genentech Inc Compuestos químicos como inhibidores de la actividad de la interleuquina-1
EP3634951B8 (en) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
WO2019032672A1 (en) * 2017-08-11 2019-02-14 Olatec Therapeutics Llc METHOD OF TREATING SCHNITZLER SYNDROME
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
WO2020037116A1 (en) * 2018-08-17 2020-02-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecule pyrin-domain targeted nlrp3 inflammasome inhibitors
JP7488267B2 (ja) 2019-01-14 2024-05-21 ザイダス・ライフサイエンシーズ・リミテッド 新規な置換スルホニル尿素誘導体
EP3999045A4 (en) * 2019-07-16 2023-11-22 Virginia Commonwealth University NLRP3 INFLAMMA SUMMER INHIBITOR COMPOUNDS AND COMPOSITIONS AND USES THEREOF
KR102409344B1 (ko) 2020-09-22 2022-06-15 가톨릭대학교 산학협력단 Nlrp3 인플라마좀 억제제 및 이의 용도
KR102409345B1 (ko) 2020-09-22 2022-06-16 가톨릭대학교 산학협력단 Nlrp3 인플라마좀 억제제 및 이의 용도
KR102430296B1 (ko) 2020-09-22 2022-08-08 가톨릭대학교 산학협력단 Nlrp3 인플라마좀 억제제 및 이의 용도
KR102472137B1 (ko) 2020-09-22 2022-11-30 가톨릭대학교 산학협력단 Nlrp3 인플라마좀 억제제 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1518846C3 (de) 1965-07-17 1974-10-17 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt Benzolsulfonylharnstoffe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
DE1518895C3 (de) 1965-12-02 1978-12-07 Hoechst Ag, 6000 Frankfurt Benzolsulfonylharnstoffe, Verfahren zu ihrer Herstellung und deren Verwendung
US3454635A (en) * 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
US3932503A (en) 1966-05-28 1976-01-13 Hoechst Aktiengesellschaft Benzenesulfonyl ureas
DE1909272A1 (de) * 1969-02-25 1970-09-10 Hoechst Ag N-[4-(ss<2-Methoxy-5-chlor-benzamido>-aethyl)-benzolsulfonyl]-N'-cyclopentylharnstoff und Verfahren zu seiner Herstellung
US3917690A (en) 1966-11-29 1975-11-04 Hoechst Ag Benzenesulfonyl ureas and process for their manufacture
DE1568648C3 (de) * 1966-12-19 1975-03-27 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt Benzolsulfonylharnstoffe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
JP2009021774A (ja) 2007-07-11 2009-01-29 Hitachi Ltd 情報処理装置、及び情報処理システム
AU2008307195B2 (en) 2007-10-04 2012-11-22 F. Hoffmann-La Roche Ag Cyclopropyl aryl amide derivatives and uses thereof
EP2731971A1 (en) * 2011-07-12 2014-05-21 Universität Zürich MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE

Also Published As

Publication number Publication date
EP2999691A4 (en) 2017-02-08
CA2913154A1 (en) 2014-11-27
WO2014190015A1 (en) 2014-11-27
JP2016522831A (ja) 2016-08-04
KR20160009667A (ko) 2016-01-26
US10343985B2 (en) 2019-07-09
AU2015258273A1 (en) 2015-12-10
CN105579433A (zh) 2016-05-11
EP2999691A1 (en) 2016-03-30
US20160052876A1 (en) 2016-02-25
MX2015016100A (es) 2017-01-11

Similar Documents

Publication Publication Date Title
BR112015029240A2 (pt) composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2015002710A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
BR112015019794A8 (pt) Composto, composição farmacêutica, agonista do receptor de esfingosina-1-fosfato, e, uso de um composto
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
BR112018003212A2 (pt) diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112014028042A2 (pt) inibidores de nampt
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112013028420A2 (pt) tratamento de mieloma múltiplo
BR112015026238A2 (pt) tratamento de câncer com dihidropirazino-pirazinas
BR112015029462A8 (pt) Inibidores de quinase
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112014009365A2 (pt) método para inibição da atividade de deubiquitinação
BR112018011562A2 (pt) novos derivados de fenil
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]